InvestorsHub Logo

ExtremelyBullishZig

11/04/17 8:32 PM

#128574 RE: kld2 #128558

Mild impairment = damaged neurons...not dead. Moderate = more dead neurons. Damaged can be repaired with a2-73. The dead neurons cannot be brought back to life.

frrol

11/04/17 8:43 PM

#128576 RE: kld2 #128558

As you say: Potentially, yes.

imho

11/04/17 8:51 PM

#128579 RE: kld2 #128558

No. And neither does Amgen, Novartis, Banner, Biogen and others.

“If we determine that our BACE1 inhibitor can prevent or delay the onset of symptoms in healthy yet high-risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.”

frol, you mentioned in a previous post that it looked like the super-responders were mildly impaired. Don't you see that as potentially suspect? Why only them? When screening and assessing such patients, the diagnostic accuracy of the MMSE for detecting these individuals with baseline MCI is questionable.

In fact Anavex selected MMSE>20 as "early", while it sounds like the companies above may target "healthy", MMSE>24 as early. BP is suspect. Anavex is not.

IMHO

PeterKarol

11/05/17 2:54 AM

#128617 RE: kld2 #128558

The Strong start from MMSE 21 average and race up then they plateau. The average score for all is 20.